Stallergenes today announced that due to the US government shutdown, the US Food and Drug Administration (FDA) has postponed the Allergenic Products Advisory Committee meeting scheduled for 5 November 2013 to discuss the Biologic License Application (BLA) for the 5 grass allergen immunotherapy tablet. The FDA has not yet confirmed a new date for the Advisory Committee meeting.